Literature DB >> 24175808

Synergism of cytotoxicity effects of triptolide and artesunate combination treatment in pancreatic cancer cell lines.

Yao Liu1, Yun-Fu Cui.   

Abstract

BACKGROUND: Triptolide, extracted from the herb Tripteryglum wilfordii Hook.f that has long been used as a natural medicine in China, has attracted much interest for its anti-cancer effects against some kinds of tumours in recent years. Artesunate, extracted from the Chinese herb Artemisia annua, has proven to be effective and safe as an anti-malarial drug that possesses anticancer potential. The present study attempted to clarify if triptolide enhances artesunate-induced cytotoxicity in pancreatic cancer cell lines in vitro and in vivo.
METHODS: In vitro, to test synergic actions, cell viability and apoptosis were analyzed after treatment of pancreatic cancer cell lines with the two agents singly or in combination. The molecular mechanisms of apoptotic effects were also explored using qRT-PCR and Western blotting. In vivo, a tumor xenograft model was established in nude mice, for assessment of inhibitory effects of triptolide and artesunate.
RESULTS: We could show that the combination of triptolide and artesunate could inhibit pancreatic cancer cell line growth, and induce apoptosis, accompanied by expression of HSP 20 and HSP 27, indicating important roles in the synergic effects. Moreover, tumor growth was decreased with triptolide and artesunate synergy.
CONCLUSION: Our result indicated that triptolide and artesunate in combination at low concentrations can exert synergistic anti-tumor effects in pancreatic cancer cells with potential clinical applications.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24175808     DOI: 10.7314/apjcp.2013.14.9.5243

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  8 in total

Review 1.  Sesquiterpene Lactones as Promising Candidates for Cancer Therapy: Focus on Pancreatic Cancer.

Authors:  Laura Cecilia Laurella; Nadia Talin Mirakian; Maria Noé Garcia; Daniel Héctor Grasso; Valeria Patricia Sülsen; Daniela Laura Papademetrio
Journal:  Molecules       Date:  2022-05-29       Impact factor: 4.927

2.  Synergistic antitumor activity of gemcitabine combined with triptolide in pancreatic cancer cells.

Authors:  Zhixin Qiao; Min He; M U He; Weijing Li; Xuanlin Wang; Yanbing Wang; Qiyuan Kuai; Changlan Li; Suping Ren; Qun Yu
Journal:  Oncol Lett       Date:  2016-03-29       Impact factor: 2.967

3.  Farnesylthiosalicylic acid sensitizes hepatocarcinoma cells to artemisinin derivatives.

Authors:  Liping Wu; Yilin Pang; Guiqi Qin; Gaina Xi; Shengnan Wu; Xiaoping Wang; Tongsheng Chen
Journal:  PLoS One       Date:  2017-02-09       Impact factor: 3.240

Review 4.  Repurposing Artemisinin and its Derivatives as Anticancer Drugs: A Chance or Challenge?

Authors:  Zhaowu Ma; Clariis Yi-Ning Woon; Chen-Guang Liu; Jun-Ting Cheng; Mingliang You; Gautam Sethi; Andrea Li-Ann Wong; Paul Chi-Lui Ho; Daping Zhang; Peishi Ong; Lingzhi Wang; Boon-Cher Goh
Journal:  Front Pharmacol       Date:  2021-12-31       Impact factor: 5.810

Review 5.  Therapeutic Potential of Certain Terpenoids as Anticancer Agents: A Scoping Review.

Authors:  Sareh Kamran; Ajantha Sinniah; Mahfoudh A M Abdulghani; Mohammed Abdullah Alshawsh
Journal:  Cancers (Basel)       Date:  2022-02-22       Impact factor: 6.639

6.  CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.

Authors:  Richard E Kast; Georg Karpel-Massler; Marc-Eric Halatsch
Journal:  Oncotarget       Date:  2014-09-30

7.  Effect of the Natural Product Triptolide on Pancreatic Cancer: A Systematic Review of Preclinical Studies.

Authors:  Chi Zhang; Xiao-Juan He; Li Li; Cheng Lu; Ai-Ping Lu
Journal:  Front Pharmacol       Date:  2017-08-25       Impact factor: 5.810

Review 8.  Advances in Synergistic Combinations of Chinese Herbal Medicine for the Treatment of Cancer.

Authors:  Xue-Qing Hu; Yang Sun; Eric Lau; Ming Zhao; Shi-Bing Su
Journal:  Curr Cancer Drug Targets       Date:  2016       Impact factor: 3.428

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.